Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study. by Lee, Meng et al.
UCLA
UCLA Previously Published Works
Title
Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A 
retrospective cohort study.
Permalink
https://escholarship.org/uc/item/8gs0898j
Journal
BMJ open, 4(12)
ISSN
2044-6055
Authors
Lee, Meng
Wu, Yi-Ling
Saver, Jeffrey L
et al.
Publication Date
2014
DOI
10.1136/bmjopen-2014-006672
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Is clopidogrel better than aspirin
following breakthrough strokes while
on aspirin? A retrospective cohort study
Meng Lee,1 Yi-Ling Wu,1 Jeffrey L Saver,2 Hsuei-Chen Lee,3 Jiann-Der Lee,1
Ku-Chou Chang,4 Chih-Ying Wu,1 Tsong-Hai Lee,5 Hui-Hsuan Wang,6
Neal M Rao,2 Bruce Ovbiagele7
To cite: Lee M, Wu Y-L,
Saver JL, et al. Is clopidogrel
better than aspirin following
breakthrough strokes while
on aspirin? A retrospective
cohort study. BMJ Open
2014;4:e006672.
doi:10.1136/bmjopen-2014-
006672
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2014-006672).
Received 23 September 2014
Revised 28 October 2014
Accepted 11 November 2014
For numbered affiliations see
end of article.
Correspondence to
Professor Bruce Ovbiagele;
Ovibes@musc.edu
ABSTRACT
Objective: There is insufficient evidence on which to
base a recommendation for optimal antiplatelet therapy
following a stroke while on aspirin. The objective was to
compare clopidogrel initiation vs aspirin reinitiation for
vascular risk reduction among patients with ischaemic
stroke on aspirin at the time of their index stroke.
Design: Retrospective.
Setting: We conducted a nationwide cohort study by
retrieving all hospitalised patients (≥18 years) with a
primary diagnosis of ischaemic stroke between 2003
and 2009 from Taiwan National Health Insurance
Research Database.
Participants: Among 3862 patients receiving aspirin
before the index ischaemic stroke and receiving either
aspirin or clopidogrel after index stroke during follow-up
period, 1623 were excluded due to a medication
possession ratio <80%. Also, 355 were excluded due to
history of atrial fibrillation, valvular heart disease or
coagulopathy. Therefore, 1884 patients were included in
our final analysis.
Interventions: Patients were categorised into two
groups based on whether clopidogrel or aspirin was
prescribed during the follow-up period. Follow-up was
from time of the index stroke to admission for recurrent
stroke or myocardial infarction, death or the end of 2010.
Primary and secondary outcome measures: The
primary end point was hospitalisation due to a new-onset
major adverse cardiovascular event (MACE: composite of
any stroke or myocardial infarction). The leading
secondary end point was any recurrent stroke.
Results: Compared to aspirin, clopidogrel was
associated with a lower occurrence of future MACE
(HR=0.54, 95% CI 0.43 to 0.68, p<0.001, number
needed to treat: 8) and recurrent stroke (HR=0.54, 95%
CI 0.42 to 0.69, p<0.001, number needed to treat: 9)
after adjustment of relevant covariates.
Conclusions: Among patients with an ischaemic stroke
while taking aspirin, clopidogrel initiation was associated
with fewer recurrent vascular events than aspirin
reinitiation.
The term ‘aspirin resistance’ has been used to
describe the failure of aspirin to produce an
expected response on one or more laboratory
measures of platelet activation and aggrega-
tion.1 Mechanistic approaches to investigating
aspirin resistance have relied mostly on ex vivo
evaluations of platelet function.2 However,
while platelet aggregability is a major contribu-
tor to occlusive vascular events,3 other factors,
such as vascular endothelial dysfunction,4 clot-
ting protein cascades5 and flow stasis6 are also
relevant. This multifactorial complexity, along
with differing methods for making ex vivo
assessments of platelet function, have made
linkage between abnormal platelet function
on laboratory indices and hard clinical events
inconsistent. As a result, defining ‘aspirin
resistance’ primarily based on currently avail-
able laboratory measures may not necessarily
be the most appropriate way of discriminating
people at high risk for future vascular events
while on aspirin.
On the other hand, the potentially more
clinically relevant term ‘aspirin treatment
failure’ has been used to describe a person
who, regardless of laboratory results, experi-
ences a breakthrough ischaemic event, such
as stroke, while receiving aspirin.7 The diag-
nosis of aspirin treatment failure is simpler
to diagnose on a consistent basis in everyday
routine clinical practice. However, the term
‘aspirin failure’ can be conceptually mislead-
ing when recurrent events occur through
mechanisms that aspirin is not expected to
influence, such as collateral failure, and
when the failure is actually due to non-
Strengths and limitations of this study
▪ It is a nationwide cohort study.
▪ All participants in our cohort received aspirin for
more than 30 days with average dose of
101.3 mg/day at the time of the index stroke.
▪ It is a retrospective cohort study and reasons for
using one specific kind of antiplatelet therapy are
not well known in this cohort study.
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adherence to prescribed aspirin rather than pharmaco-
logical ineffectiveness. Although alternative antiplatelet
agents are often considered, as mentioned in prevailing
expert consensus clinical practice guidelines, there is
insufficient evidence on which to base a recommenda-
tion for optimal antiplatelet therapy following a stroke
while on aspirin.8
The objective of this study was to compare the effect-
iveness of clopidogrel vs aspirin for vascular risk reduc-
tion among patients with ischaemic stroke who were on
aspirin treatment at the time of their index stroke.
METHODS
Study design and dataset
We conducted a nationwide cohort study by retrieving
all hospitalised patients (≥18 years) with a primary diag-
nosis of ischaemic stroke between 2003 and 2009 from
Taiwan National Health Insurance Research Database
(NHIRD). Taiwan has launched a compulsory National
Health Insurance programme since 1995, which covers
99% of the population and reimburses for outpatients,
inpatient services as well as prescription drugs. All con-
tracted institutions must file claims according to stand-
ard formats, which later transform into the NHIRD. The
accuracy of diagnosis of major diseases in the NHIRD,
such as stroke, has been validated.9
Study population
We identified all hospitalised patients who were admit-
ted with a primary diagnosis of ischaemic stroke
(International Classification of Diseases, Ninth Revision
(ICD-9) codes 433, 434, 436) among subjects
(≥18 years) encountered between 2003 and 2009. This is
a nationwide study that included all available and eli-
gible patients. We defined the first ischaemic stroke
during study period as the index stroke. We retrieved
the information of medications prescribed by physicians
prior to index stroke among these patients from the
pharmacy prescription database. Only patients with
ischaemic stroke who received continuous aspirin treat-
ment ≥30 days before the index stroke were included in
our study cohort. The Charlson index was used as a
measure for overall severity of comorbidities for index
stroke.10 Comorbidities were confirmed by ICD-9 codes
based on the diagnoses of hospitalisation for index
stroke. We excluded patients with atrial fibrillation,
valvular heart disease or coagulopathy, since anticoagu-
lants, rather than antiplatelet agents, are generally
more suitable for secondary stroke prevention among
these patients. Information regarding patients’ medica-
tions during the follow-up period was retrieved from the
pharmacy prescription database. Patients were cate-
gorised into two groups based on whether clopidogrel
or aspirin was prescribed during the follow-up period.
Patients were excluded if they switched antiplatelet
therapy between aspirin and clopidogrel during the
follow-up period to make the analyses straightforward.
The Taiwan National Health Insurance Bureau provides
reimbursement for the use of clopidogrel in patients
with ischaemic stroke who are allergic to aspirin or have
peptic ulcer (the latter confirmed by prior or current
pan-endoscopy results). Although ‘aspirin treatment
failure’ is not one of the prespecified criteria for clopi-
dogrel use, the Bureau typically provides reimbursement
in these circumstances. As such, physicians generally
have broad latitude to prescribe clopidogrel or aspirin
based on their personal preferences. Patients were
excluded if their medication possession ratio (number
of days drug supplied divided by the number of days in
the follow-up period) was <80% or clopidogrel or aspirin
was not prescribed within 30 days before an end point to
reduce bias from poor drug adherence or antiplatelet-
discontinuation effects.11 12
Main outcome measures
The primary end point was the first event of a new-onset
major adverse cardiovascular event (MACE: composite of
any stroke (ischaemic or haemorrhagic) or myocardial
infarction). The leading secondary end point was the first
event of any recurrent stroke (ischaemic or haemorrhagic)
alone. Additional secondary end points were ischaemic
stroke, intracranial haemorrhage (codes 430–432), fatal
stroke, myocardial infarction (code 410) and all-cause
mortality. Follow-up was from time of the index stroke to
admission for the first event of recurrent stroke (codes
430–434, 436) or myocardial infarction, death, or the end
of 2010. National Health Insurance is a compulsory pro-
gramme in Taiwan, and moving out of the country, which
is supposed to be scarce among patients with stroke, is
almost the only reason, besides death, for being withdrawn
from this programme. A previous study from the Taiwan
NHIRD also used ‘withdrawn’ from this programme to
define death.13 Therefore, we defined death as in-hospital
death or withdrawal of the patient from the National
Health Insurance programme.
Statistical analysis
The baseline characteristics of two treatment groups
were compared using student t test for continuous vari-
ables and χ2 test for categorical variables. Kaplan-Meier
plots were generated, and the log-rank test was used to
evaluate the difference between curves. We employed
Cox’s proportional hazard model to estimate the
unadjusted and adjusted HRs and 95% CIs, which con-
sidered the aspirin group as the reference group. The
model was adjusted for baseline age, gender, hyperten-
sion, diabetes, prior stroke, prior ischaemic heart
disease, hyperlipidaemia, gastrointestinal bleeding or
peptic ulcer, Charlson index, statin use, other antiplate-
let drugs use, ACE inhibitors or angiotensin receptor
blockers use, calcium channel blockers use and diuretics
use during the follow-up period. Stratified analysis for
MACE was conducted to clarify whether baseline
characteristics would influence the association between
antiplatelet treatment strategy and outcomes. The data
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were processed with the SAS statistical software, V.9.2
(SAS Institute Inc, Cary, North Carolina, USA) and the
Statistical Package for the Social Sciences, V.17.0 (SPSS
Inc, Chicago, Illinois, USA). A two sided p value <0.05
was considered to be statistically significant.
RESULTS
Among 3862 patients receiving aspirin before the index
ischaemic stroke and receiving either aspirin or clopido-
grel after index stroke during the follow-up period, 1623
were excluded due to a medication possession ratio
<80%, or clopidogrel or aspirin not being prescribed
within 30 days of a prespecified end point. Also, 355
patients were excluded due to history of atrial fibrilla-
tion, valvular heart disease or coagulopathy. Therefore,
1884 patients were included in our final analysis. There
were no significant differences in baseline characteristics
(eg, age, sex and Charlson index score) between
included vs excluded patients.
Among study-eligible patients, the mean age was 71.1
±10.0 years old and 40% were women. Characteristics of the
participants at baseline and during follow-up period by dif-
ferent types of antiplatelet agents are shown in table 1. The
daily aspirin dose before index stroke was not different
between groups (101.4 mg vs 100.9 mg) and the average
daily dose was 100.9 mg for aspirin vs 74.6 mg for clopido-
grel during the follow-up period. The baseline character-
istics between the two groups were not significantly
different except that patients receiving clopidogrel were
more likely to have gastrointestinal bleeding or peptic ulcer,
likely because peptic ulcer is an indication for clopidogrel
use under the Taiwan National Health Insurance Bureau
reimbursement policy, that is, treatment confounding by
indication. Patients receiving clopidogrel were more likely
to use statins and diuretics during the follow-up period.
During the mean follow-up of 2.4 years, there were
661 MACE and 601 recurrent strokes. Kaplan-Meier
curves suggested clopidogrel, as compared to aspirin,
reduced the hazards of MACE (figure 1). For MACE,
the annual event rate was 9.9% in clopidogrel group
and 15.8% in aspirin group. For recurrent stroke, the
annual event rate was 8.8% in clopidogrel group and
14.5% in aspirin group. Compared to aspirin, clopido-
grel was associated with a significantly lower occurrence
of future MACE (adjusted HR=0.54, 95% CI 0.43 to
0.68, p<0.001) and recurrent stroke (adjusted HR=0.54,
95% CI 0.42 to 0.69, p<0.001) after adjustment of rele-
vant covariates. For the secondary end points, the
pattern of benefit for clopidogrel users was consistent
across several end points, including ischaemic stroke
(adjusted HR=0.55, 95% CI 0.43 to 0.71, p<0.001),
intracranial haemorrhage (adjusted HR=0.40, 95% CI
0.17 to 0.97, p=0.041), and composite of MACE and all-
cause mortality (adjusted HR=0.66, 95% CI 0.55 to
0.78, p<0.001). The risk of all-cause mortality was not
different between clopidogrel and aspirin users
(adjusted HR=0.97, 95% CI 0.73 to 1.30, p=0.853;
table 2). The benefit of clopidogrel was consistent
across eight subgroups of baseline characteristics in
stratified analysis for future MACE (figure 2).
DISCUSSION
The ‘breakthrough’ ischaemic cerebrovascular event in a
patient on aspirin is a common scenario frequently encoun-
tered by clinicians caring for patients with stroke. Strategies
for instituting an antithrombotic regimen to prevent future
vascular events in such patients vary widely, largely because
there is no dedicated clinical trial evidence to guide practi-
tioners. Few patient registries have the scale, relevant anti-
platelet information, or long term follow-up assessment
capacity to provide insights into this issue. On the basis of
the Taiwan NHIRD, we found, in the event of stroke while
on aspirin, switching to clopidogrel is associated with fewer
vascular events and fewer recurrent strokes. While these
observational data can only be seen as suggestive, the
current results may provide clinicians modest evidence-
based guidance while they wait for additional data from ran-
domised controlled trials of antithrombotic regimens vs
aspirin reinitiation among aspirin treatment failures.
Currently, clopidogrel, aspirin and aspirin plus
extended-release dipyridamole are recommended as
initial first-line options in preventing recurrent stroke.8
Indeed, clinical trials suggest that aspirin plus extended-
release dipyridamole has superior efficacy to aspirin
monotherapy,14 and clopidogrel appears to have similar
effects on secondary stroke prevention when compared
to aspirin plus extended-release dipyridamole.15 While
there have been no dedicated head to head trials of
clopidogrel vs aspirin among patients with ischaemic
stroke, based on the aforementioned clinical trial data,
one could indirectly infer that clopidogrel may be better
than aspirin for secondary stroke prevention in patients
with ischaemic stroke overall. Also, greatest platelet
inhibitory effect of clopidogrel is found in people with
the least inhibition of platelet aggregation by aspirin.16
As such it is conceivable that clopidogrel may confer the
greatest benefit for patients with aspirin treatment
failure.
We found patients receiving aspirin, as compared to
clopidogrel, tended to take another antiplatelet agent
together and had higher risk of intracranial haemor-
rhage. This finding is consistent with a recent
meta-analysis and the PRoFESS trial showing that when
compared to clopidogrel monotherapy, long-term
aspirin-based dual-antiplatelet therapy is linked to
higher risk of intracranial haemorrhage among patients
with ischaemic stroke.15 17 Additionally, in the CAPRIE
trial, clopidogrel, as compared to aspirin, was associated
with a non-significant number of intracranial haemor-
rhage events among a cohort of patients at high risk for
recurrent ischaemic events.18
A post hoc analysis of patients with aspirin failure and
recent lacunar stroke from the Secondary Prevention of
Small Subcortical Strokes Trial (SPS3) cohort suggested
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the addition of clopidogrel did not result in reduction
of vascular events vs continuing aspirin only.19 Several
differences exist between these two cohorts. First, the
exact dosage and duration of aspirin use before the
index stroke were not known in SPS3 cohort but all par-
ticipants in our cohort were receiving aspirin for more
than 30 days with average dose of 101.3 mg/day at the
time of the index stroke. Second, the daily dose of
aspirin was 325 mg in SPS3 vs 100.9 mg in the current
cohort during study period. Third, SPS3 was conducted
in Western countries and the current study was con-
ducted in an Asian country. Asian patients with stroke
have higher possibility of intracranial stenosis20 and a
study suggested that adding clopidogrel along with
aspirin is more effective than aspirin alone in reducing
microembolic signals in people with intracranial symp-
tomatic stenosis.21
This study has several limitations. First, it is a retro-
spective cohort study and reasons for using one specific
kind of antiplatelet therapy are not well known in this
cohort study. Second, information on a few established
stroke risk factors, for example, smoking and blood pres-
sure levels during the follow-up period, are not provided
in NHIRD. However, these limitations were not likely to
greatly bias the overall results. Third, ischaemic stroke
type is not provided directly in the NHIRD. Fourth,
several patients were excluded from the final analysis
due to the nature of the study question and our strict
inclusion criteria. Our strict inclusion criteria were
driven largely by a desire to exclude patients with poor
drug adherence, since such a situation may have con-
founded our ability to properly address the study ques-
tion. Also, there were no significant differences in
baseline characteristics between included vs excluded
patients. Fifth, some non-steroidal anti-inflammatory
drugs (NSAIDs), such as ibuprofen, may compete with
aspirin for the cyclo-oxygenase 1 binding site and signifi-
cantly interfere with the antiplatelet activity of aspirin.22
We did not explore the impact of NSAIDs use for the
current study because the NSAIDs were readily available
outside the prescription, and the exact dose and dur-
ation of NSAIDs use were difficult to standardise. It is
not possible that use of NSAIDs, which is more likely to
interfere with antiplatelet activity of aspirin but not with
that of clopidogrel, was a significant determinant of
higher recurrent vascular events in aspirin group. Sixth,
we did not adjust for socioeconomic status of patients
because the link between data from the NHIRD and
information of socioeconomic status, such as income, is
Table 1 Characteristics of patients at baseline and during the follow-up period according to antiplatelet agents
Demographic characteristic Clopidogrel (N=384) Aspirin (N=1500) p Value
Men, n (%) 229 (59.6%) 895 (59.7%) 0.991
Age, years, mean±SD 70.8±9.5 71.1±10.2 0.574
Interval from index stroke to enrolment, day, median (IQR) 18 (13–32) 16 (11–26) 0.113
Comorbidity, n (%)
Hypertension 220 (57.3%) 780 (52.0%) 0.064
Diabetes mellitus 169 (44.0%) 736 (49.1%) 0.077
Ischaemic heart disease 64 (16.7%) 284 (18.9%) 0.307
Prior stroke/TIA 87 (22.7%) 280 (18.7%) 0.078
Hyperlipidaemia 78 (20.3%) 327 (21.8%) 0.527
GI bleeding/peptic ulcer 72 (18.8%) 39 (2.6%) <0.001
Charlson index 0.8±0.9 0.8±1.0 0.774
Medication during the follow-up period
Statin 170 (44.3%) 568 (37.9%) 0.022
Other antiplatelet drugs* 22 (5.7%) 131 (8.7%) 0.055
ACEI/ARB 160 (41.7) 589 (39.3) 0.391
CCB 207 (53.9) 822 (54.8) 0.754
Diuretics 84 (21.9) 261 (17.4) 0.043
*Dipyridamole, ticlopidine, cilostazole, or aspitin+dipyridamole.
ACEI: ACE inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; GI, gastrointestinal; TIA, transient ischaemic attack.
Figure 1 Kaplan-Meier curves for major adverse
cardiovascular events among clopidogrel and aspirin groups.
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not allowed in Taiwan. Seventh, patients treated with clo-
pidogrel received lipid-lowering therapy more frequently,
but we do not know the exact reason for this. On one
hand, it should be pointed out that all included patients
had roughly similar compliance since medication posses-
sion ratios were >80%. On the other hand, although
there is nationwide regulation of antiplatelet drug pre-
scriptions, it is not inconceivable that some doctors who
were more willing to use the antiplatelet drug with
higher cost (clopidogrel) were also more inclined to
prescribe statin drugs. Finally, our cohort included only
Asian patients and the generalisability of the findings to
other races is unknown. Future studies will need to
include non-Asian patients.
As has been emphasised in the literature, patients who
have an ischaemic stroke while taking aspirin need
detailed work up to identify the mechanism of their
event.8 23 Many of these mechanisms will have a specific
indicated therapy, such as carotid endarterectomy or
stenting for symptomatic carotid stenosis, anticoagula-
tion for atrial fibrillation and haemodynamic manage-
ment for collateral failure. If platelet aggregation is
determined to be a likely contributing factor to the
event, the observational data in our study suggest that,
among patients with ischaemic stroke who experience a
stroke while on aspirin, that is, the so-called ‘aspirin
treatment failures’, initiation of clopidogrel may be a
better long-term choice than reinitiation of aspirin for
Table 2 Occurrence of primary and secondary end points and unadjusted and adjusted HRs by clopidogrel vs aspirin
Clopidogrel,
N=384
Aspirin,
N=1500
Unadjusted HR
(95% CI) p Value
Adjusted HR
(95% CI) p Value
Primary outcome
MACE 91 (23.7%) 570 (38.0%) 0.54 (0.43 to 0.68) <0.001 0.54 (0.43 to 0.68) <0.001
Secondary outcomes
Any recurrent stroke 81 (21.1%) 520 (34.7%) 0.53 (0.42 to 0.67) <0.001 0.54 (0.42 to 0.69) <0.001
Ischaemic stroke 75 (19.5%) 470 (31.3%) 0.54 (0.43 to 0.70) <0.001 0.55 (0.43 to 0.71) <0.001
Intracranial
haemorrhage
6 (1.6%) 50 (3.3%) 0.41 (0.18 to 0.96) 0.041 0.40 (0.17 to 0.97) 0.041
Fatal stroke 10 (2.6%) 52 (3.5%) 0.71 (0.36 to 1.40) 0.327 0.76 (0.38 to 1.53) 0.443
Myocardial infarction 10 (2.6%) 50 (3.3%) 0.65 (0.33 to 1.28) 0.208 0.50 (0.24 to 1.05) 0.067
All-cause mortality 64 (16.7%) 229 (15.3%) 0.93 (0.71 to 1.23) 0.618 0.97 (0.73 to 1.30) 0.853
MACE+ all-cause
mortality
155 (40.4%) 799 (53.3%) 0.66 (0.55 to 0.78) <0.001 0.66 (0.55 to 0.78) <0.001
Model was adjusted for baseline age, gender, hypertension, diabetes, prior stroke, prior ischaemic heart disease, hyperlipidaemia,
gastrointestinal bleeding or peptic ulcer, Charlson index, statin use, other antiplatelet drugs use, ACE inhibitors or angiotensin receptor
blockers use, calcium channel blockers use and diuretics use during follow-up period.
MACE, major adverse cardiovascular event (composite of stroke and myocardial infarction).
Figure 2 Stratified analysis for future adjusted risks of major adverse cardiovascular events according to baseline
characteristics (clopidogrel vs aspirin).
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future vascular risk reduction. Still, the results should be
interpreted in the light of the several limitations as
described above. Before considering dedicated rando-
mised clinical trials of clopidogrel initiation vs aspirin
reinitiation among patients with ischaemic stroke, pro-
spective cohort studies should explore this issue utilising
more precise information on the underlying mechanism
of the index stroke and treatment of post-stroke risk
factors.
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